Rijuven Debuts CardioSleeve, an FDA Cleared Stethoscope Attachment with 3-Lead ECG and Digital Auscultation that Wirelessly Connects to Mobile Devices
Wexford, PA (PRWEB) July 10, 2013 -- Startup Rijuven Corp. (http://www.rijuven.com) is announcing the debut of CardioSleeve v1.0, the first FDA cleared stethoscope accessory device for clinicians to acquire 3-Lead ECG and Digital Auscultation at any point of care. CardioSleeve enhances the traditional stethoscope by recording, displaying and analyzing electrical and acoustical footprints of the heart in real time via any wirelessly connected portable device. Rijuven received FDA clearance for CardioSleeve v1.0 on June 25, 2013. The device, slated as the first accessory device that enhances the diagnostic capability of the traditional stethoscope, is expected to be available by Q4, 2013.
During the physical examination of a patient, heart sound auscultation is subjective to the hearing, experience and training limitations of the clinician, which can lead to missed diagnosis and additional costly tests. The traditional ECG requires expensive cart machines with wired electrodes, which restricts access.
Rijuven combines and improves on these cardio-diagnostic processes by allowing a clinician to attach the CardioSleeve to an existing stethoscope to acquire the digital acoustic and electric footprints of the heart and transmits them to a mobile device for real time analysis at any point of care.
“With over 40 million stethoscopes, used worldwide, Rijuven’s innovative add-on CardioSleeve digital technology will help revolutionize assessment and diagnosis of patients far more effectively, efficiently, and empathetically at any point of care, in almost any clinical scenario...” said Raj Kapoor, MD, FCCP, President, Rijuven Corp.
CardioSleeve’s patent pending device and mobile app platform attaches to any stethoscope to offer the following features:
• Digital Auscultation with ECG
• Murmur Detection and Analysis
• 3- Lead ECG
• Digital Caliper
• Cardiac Index Est.
• Wireless connectivity to smartphone, tablet, laptop and PC
• Cloud EMR Archival
The merging of innovative sensor technology and mobile app allow a clinician to acquire, analyze and share digital heart sound recordings and 3-Lead ECG more timely and cost effectively, while maintaining control of the diagnostic decision making process.
Rijuven is planning the release of CardioSleeve v 1.0 to clinicians in Q4 2013, with additional device and app diagnostics to follow to create a pipeline of compelling products across multiple specialties. Rijuven also plans to introduce consumer wellness devices utilizing its underlying patent pending technology.
“Nothing better epitomizes Rijuven’s DNA and unique innovative spirit, than the revolutionary technology behind the CardioSleeve. It allows a physician to instantly acquire and analyze acoustic and electrical footprints of the patient’s heart on any mobile device at any point of care. This unquestionably enhances quality patient care, saves lives and reduces health care cost.” said Kapoor.
About the Company: Rijuven Corp. was founded by Raj Kapoor, MD, FCCP and technologist Evens Augustin to commercialize medical devices that have a world impact. The team of clinicians, technologists, designers and innovation strategists have come together to transform medical device markets and revolutionize care delivery through the use of select innovations that increase outcomes, drive down costs and expand care access.
For more information, please visit: http://www.rijuven.com or email: media (at) rijuven (dot) com.
Justin Bass, Rijuven Corp., http://www.rijuven.com, +1 412-404-6292 103, [email protected]
Share this article